Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
David J
DJ
Back
Andrew
A
Owen
Saye H
SH
Khoo
D000480:Alkynes; D019380:Anti-HIV Agents / Q000378:metabolism / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D048588:Benzoxazines; D003521:Cyclopropanes; D065702:Cytochrome P-450 CYP2B6; D015658:HIV Infections / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D010078:Oxazines / Q000378:metabolism / Q000493:pharmacokinetics*; D010089:Oxidoreductases, N-Demethylating / Q000235:genetics*; D011110:Polymorphism, Genetic
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D001189:Aryl Hydrocarbon Hydroxylases; C585599:CYP2B6 protein, human; D065702:Cytochrome P-450 CYP2B6; D010089:Oxidoreductases, N-Demethylating; C098320:efavirenz